Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study of Nivolumab in Combination with 177Lu-girentuximab for Kidney Cancer, STARTLITE 2 Study

Trial Status: active

This phase II trial studies the side effects and best dose of 177Lu-girentuximab when given together with nivolumab in treating patients with kidney cancer. 177Lu-girentuximab is a type of treatment called radioimmunotherapy, and it includes an antibody (similar to antibodies made by the immune system to help fight infections) and a radioactive particle that gives off a small amount of radiation. 177Lu-girentuximab targets the protein CAIX, which is on the cancer cells of about 90% of people who have kidney cancer. The antibody part of the therapy (girentuximab) attaches to the CAIX protein and delivers the radioactive particle (lutetium-177) directly to the cancer cells. The radioactive particle gives off radiation to kill the cancer cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with 177Lu-girentuximab may kill more tumor cells in patients with renal cell carcinoma.